(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Early diagnosis leads King Charles to scale back cancer treatment in the new year- Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
- Remain Cool and Solid: Top Summer Food sources for 2024
- Norovirus is spreading earlier again this year, wastewater data shows
- Hubble sees spiral galaxy in Lion's heart | Space photo of the day for Nov. 4
- This Asian country is the next hot travel destination, and this is one of its best hotels
- Cases of norovirus are on the rise just in time for the holiday season
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- The 25 Most Notable Style Crossroads in History
